NEWSLETTER

ISGIDAR

VOL. 19, NO. 1 FEBRUARY 1993

INTERNATIONAL STUDY GROUP INVESTIGATING DRUGS AS REINFORCERS

CORRESPONDENCE

ABOUT ISGIDAR:

Richard A. Meisch
Department of Psychiatry
The University of Texas
Health Science Center at Houston
1300 Moursund
Houston, TX 77030-3497
713-794-1440

ABOUT ISGIDAR NEWSLETTER:

John R. Hughes Human Behavioral Pharmacology Laboratory Department of Psychiatry University of Vermont 38 Fletcher Place Burlington, VT 05401-1419 802-660-3065

ISGIDAR SCIENTIFIC MEETING -- 1993

The 1993 annual ISGIDAR meeting will be held Saturday, June 12th, at the Toronto Hilton and the Toronto Sheraton Centre in Toronto, Ontario, Canada. PLEASE NOTE THIS IS SATURDAY NOT SUNDAY. As usual, the meeting will be held as a satellite session immediately preceding the annual scientific meeting of the Committee on Problems of Drug Dependence. ISGIDAR registration will begin at 8:30 am. The registration fee is \$20. Paper presentations will be scheduled between 9 am and 5 pm, and the business meeting with election of officers will be held from 5 to 5:30 pm.

To present a paper at the ISGIDAR meeting, send a 300-word abstract by May 1, 1993 to Dick Meisch at the address listed above. Please note that papers submitted to ISGIDAR should not also be presented at CPDD. The amount of time available for each talk will depend on the number of papers submitted but will not be less than 20 minutes.

We are again arranging to have lunch catered by the hotel, so that we can eat together and continue discussions from the morning session. The lunch is likely to cost approximately \$16 per person. Invitations for this lunch will be sent together with the mail ballot. You may return your lunch reservation in a separate envelope from the ballot to retain your anonymity. We will be requesting that members RSVP with money for their lunch when they return the ballot. We are investigating ways to subsidize this lunch (but it will not be free ...).

Submit manuscripts to

Dr. Richard Meisch Department of Psychiatry The University of Texas Health Science Center at Houston 1300 Moursund Houston, Texas 77030-3497

DEADLINE FOR SUBMISSION: May 1, 1993

MESSAGE FROM THE PRESIDENT

NOMINATIONS FOR MEMBERSHIP

Members are also reminded that if they wish to nominate a new member of ISGIDAR, they should submit the names to Dick Meisch before April 15. We will mail a ballot with the nominees' names to current ISGIDAR members for voting, to be sent out April 16. The outcome of the mail ballots will be announced at the meeting on June 12th.

INVITED SPEAKERS FOR THE 1993 MEETING

We are seeking suggestions for speakers to invite to the 1993 meeting. Invited speakers should be individuals who do not regularly attend the ISGIDAR meeting, and who are doing interesting research related to drugs as reinforcers. They will be paid a \$100 honorarium. Members are urged to submit suggestions to Richard Meisch.

1993 TRAVEL AWARD: STUDENT PAPER COMPETITION

ISGIDAR will again sponsor a Student Paper Competition Award for a new investigator to present a paper on drug self-administration research. Up to \$500 in reasonable and documented travel costs will be paid to the winner to attend the meeting of the Committee on Problems of Drug Dependence, 1993 to present a paper at the ISGIDAR satellite session. Those who did not receive the award, but who did receive good reviews will be encouraged to present their papers at the ISGIDAR meeting.

ELIGIBILITY: Applicants must be enrolled in a graduate program and be working toward a doctorate or have received their doctorate within the last five years (after June 1, 1988).

Applicants who are not ISGIDAR members must be sponsored by an ISGIDAR member.

The research to be reported at ISGIDAR must not already be published.

MANUSCRIPT REQUIREMENTS: Papers should not be more than 10 pages excluding figures and references.

The length and scope of the paper should be consistent with a 20-25 minute slide presentation. Please include paper title, name, address, phone number and author's signature on the cover page of the manuscript.

The signature and typed name of the author's sponsor should also appear on the cover page after a statement indicating that the applicant made a significant scientific contribution to the research.

Submit four copies, double-spaced.

REVIEW: Each manuscript will be independently reviewed by the ISGIDAR officers for originality, scientific contribution, sound methodology and clarity of the manuscript.

Blind review is possible upon request.

Reviewers will not participate in the review of papers from their own institution.

Submit manuscripts to

Dr. Richard A. Meisch

Department of Psychiatry and Behavioral Sciences University of Texas Health Science Center at Houston

1300 Moursund St.

Houston, Texas 77030-3497

DEADLINE FOR SUBMISSION: April 15, 1993

DRUG REINFORCEMENT TOPIC AT THE SOCIETY FOR THE QUANTITATIVE ANALYSIS OF BEHAVIOR MEETING

The Society of the Quantitative Analysis of Behavior will be meeting May 26 and 27 immediately prior to the Annual Convention of the Association for Behavior Analysis in Chicago. This meeting is organized by J.A. Nevin and W.K. Bickel and will address issues related to drug self-administration and reinforcement. Included among the presenters are William Baum, Warren Bickel, John Boren, Marilyn Carroll, Charles Catavia, Richard DeGrandpre, Steve Dworkin, Ed Fantino, Gene Heymen, Tony Nevin and Ken Silverman. Topics include: behavioral economics, income effects on drug taking, abuse liability, contractual factors controlling drug reinforcement, elasticity of ethanol, neurobiology and predicting relapse. For further information contact Warren K. Bickel, Ph.D., Human Behavioral Pharmacology Laboratory, University of Vermont, Department of Psychiatry, 38 Fletcher Place, Burlington, VT 05401-1419. Telephone 802-660-3060. Fax 802-660-3064.

FELLOWSHIP POSITIONS

Alcohol and Drug Abuse Research Center Harvard Medical School - McLean Hospital

Post-doctoral research training (National Research Service Awards). The Alcohol and Drug Abuse Research Center is a multidisciplinary research program which includes basic, clinical and treatment research. Trainees may participate in research on the behavioral pharmacology of substance abuse; the neuroendocrine consequences of cocaine and alcohol abuse; the effects of drug abuse on the brain as assessed by brain imaging techniques (MRI, MRS, SPECT and EEG) and the evaluation of the safety and effectiveness of new pharmacotherapies for the treatment of drug abuse. The clinical research programs emphasize analysis of the antecedents and consequences of drug abuse by women. The McLean Hospital is an affiliate of the Harvard Medical School and the Massachusetts General Hospital, located in Belmont, a suburb of Boston. A Ph.D., M.D., or M.D./Ph.D. is required. Salary is commensurate with experience (PGY 1 to (PGY 7). Please send a curriculum vita, reprints of some recent papers, a brief statement about your research interests and goals, and the names of three references (including complete address and telephone number) to Dr. Jack H. Mendelson, Professor Psychiatry (Neuroscience) or Dr. Nancy K. Mello, Professor of Psychology (Neuroscience), Co-Directors, Alcohol and Drug Abuse Research Center, McLean Hospital, 115 Mill Street, Belmont, MA 02178. McLean Hospital is an equal opportunity/Affirmative Action Employer.

Johns Hopkins University School of Medicine

POSTDOCTORAL FELLOWSHIP. Develop and implement preclinical behavioral pharmacology research related to substance abuse in a stimulating and productive environment. Our laboratory has an ongoing program of research characterizing the behavioral pharmacology of compounds acting at the GABA/benzodiazepine receptor complex. Studies in baboons and rats are investigating the reinforcing, discriminative stimulus, physical dependence producing and memory-impairing effects of these drugs. Other studies are examining the behavioral pharmacology of a variety of other abused substances. The fellow will be trained in relevant procedures and will contribute to the preclinical research program. The training program is part of a preclinical and clinical training program in the behavioral pharmacology of abused drugs and there are opportunities to participate in related human research. Ph.D. and research experience are required. Send letter of interest, vita and phone numbers of three references to: Roland Griffiths, Ph.D., BPRU, Behavioral Biology Research Center, Johns Hopkins Bayview Research Campus, 5510 Nathan Shock Drive, Baltimore, MD 21224. Telephone (410) 550-0034.

JOHNS HOPKINS MEDICAL SCHOOL. Postdoctoral human research positions available in a stimulating and productive environment with excellent clinical and research resources. BEHAVIORAL MEDICINE: Develop and implement behavioral medicine research in both laboratory and clinic related to smoking cessation, asthma and compliance with medical regimens. Health psychology or clinical background, research experience and analytical skills desirable. DRUG ABUSE TREATMENT: Develop and implement clinical drug abuse research on behavioral and pharmacological drug abuse treatments. Clinical or experimental psychology Ph.D., with research experience. BEHAVIORAL PHARMACOLOGY: Develop and implement human laboratory research related to drugs of abuse, especially opioid drug discrimination. Experimental background and research experience required. Minorities encouraged to apply. USPHS stipend levels based on experience. Send vita, letter of interest and names and telephone numbers of three references to George E. Bigelow, Ph.D., BPRU, Behavioral Biology Research Center, 5510 Nathan Shock Drive, Johns Hopkins/Key Medical Center, Baltimore, MD 21224. Telephone (410) 550-0035.

Medical College of Virginia

Postdoctoral training is available in the Department of Pharmacology and Toxicology for experimental psychologists interested in entering the fields of behavioral pharmacology or behavioral toxicology. Ongoing research centers on the effects of drugs of abuse and inhalants using such procedures as scheduled controlled behavior, drug discrimination and drug self-administration. Studies are underway using mice, rats, squirrel monkeys and rhesus monkeys. Candidates are being sought who have experience in operant behavior research in animals and who can demonstrate a potential for developing a career in biobehavioral research. Experience in pharmacology and/or toxicology research is desirable, but not essential. Opportunities are available for coursework in pharmacology and toxicology to supplement an active research program. The Department of Pharmacology and Toxicology includes both pharmacologists and psychologists, with a number of other postgraduate psychology fellows contributing to a highly interdisciplinary research environment. Interested applicants should send a CV and letter of research interests to Dr. Robert L. Balster, Department of Pharmacology and Toxicology, Medical College of Virginia, Box 613, Richmond, VA 23298-0613.

University of Texas Health Science Center-Houston, School of Medicine, Substance Abuse Research Center.

Postdoctoral positions in Behavioral Pharmacology supported by a NIDA Training Grant awarded to the Substance Abuse Research Center (SARC) at the University of Texas Health Science Center at Houston. SARC consists of 12 faculty members actively engaged in research supported by nine NIH grants and a drug contract. Three components of SARC are involved in training: (1) the Addictive Behaviors Clinic with a staff of five counselors and two nurses, (2) the Human Behavioral Pharmacology Laboratory containing 13 human operant chambers, and (3) the Preclinical Laboratories which have a large facility for rodent and primate research. Most of the research activities are concerned with the treatment of substance abusers, the study of human and animal drug self-administration, and the study of drug effects upon human and animal behavior. Interested individuals should send a C.V. and letter of interest to: John Grabowski, Ph.D.(Clinical research/human drug self-administration), Richard Meisch, M.D., Ph.D. (animal drug self-administration), Don R. Cherek, Ph.D. (human behavioral pharmacology) or Peter B. Silverman, Ph.D. (animal behavioral pharmacology) at Substance Abuse Research Center, Department of Psychiatry & Behavioral Sciences, Univ. Texas Health Science Center, 1300 Moursund St., Houston, TX 77030-3497. (713)-792-7925.

BIBLIOGRAPHY

This is a listing of recent publications on drug reinforcement or on the behavioral pharmacology of drugs of abuse by ISGIDAR members:

RA = published, reprints available IP = in press SU = submitted NA = published, reprints not available

Nancy A. Ator, Ph.D.
Division of Behavioral Biology
Behavioral Biology Research Center
Hopkins Bayview Research Campus
5510 Nathan Shock Dr., Suite 3000
Baltimore, MD 21224

Ator, N.A., Griffiths, R.R. Oral self-administration of triazolam, diazepam and ethanol in the baboon: drug reinforcement and benzodiazepine physical dependence. <u>Psychopharm</u> 108:301-312, 1992. (RA)

Ator, N.A., Griffiths, R.R. Differential sensitivity to midazolam discriminative-stimulus effects following self-administered versus response-independent midazolam. <u>Psychopharm</u>. (IP)

Griffiths, R.R., Sannerud, C.A., Ator, N.A., Brady, J.V. Zolpidem behavioral pharmacology in baboons: Self-injection, discrimination, tolerance and withdrawal. <u>JPET</u> 260:1199-1208, 1992. (RA)

Sannerud, C.A., Ator, N.A., Griffiths, R.R. Behavioral pharmacology of abecarnil in baboons: self-injection, drug discrimination and physical dependence. <u>Beh Pharm</u> 3:507-516, 1992. (RA)

Dr. Robert L. Balster
Department of Pharmacology and Toxicology
Medical College of Virginia
Box 613
Richmond, VA 23298-0613

Balster, R.L., Grech, D.M., Bobelis, D.J. Drug discrimination analysis of ethanol as a N-methyl-D-aspartate antagonist. <u>Eur J Pharm</u> 222:39-42, 1992. (RA)

Balster, R.L., Wiley, J.L., Tokarz, M.E., Knisely, J.S. Effects of ethanol on fixed-ratio performance in short sleep and long sleep mice. <u>Drug Alcohol Dep</u> 31:65-95, 1992. (RA)

Bobelis, D.J., Balster, R.L. Pharmacological specificity of the discriminative stimulus properties of 2-amino-4, 5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid (NPC 12626), a competitive N-methyl-D-aspartate receptor antagonist. <u>IPET</u>) 264:845-853, 1993. (RA)

Evans, E.B., Balster, R.L. Inhaled 1,1,1-trichloroethane produced physical dependence in mice: Effects of drugs and vapor on withdrawal. <u>JPET</u> 264:726-733, 1993. (RA)

Gold, L.H., Balster, R.L. Effects of NMDA receptor antagonists in squirrel monkeys trained to discriminate the competitive NMDA receptor antagonist NPC 12626 from saline. <u>Eur J Pharm</u> 230:285-292, 1993. (RA)

Mansbach, R.S., Balster, R.L. Effects of mazindol on behaviors maintained or occasioned by cocaine. <u>Drug Alcohol Dep</u> 31:183-191, 1993. (RA)

Warren K. Bickel, Ph.D. Human Behavioral Pharmacology Laboratory University of Vermont Department of Psychiatry 38 Fletcher Place Burlington, VT 05401-1419

Bickel, W.K., Hughes, J.R., DeGrandpre, R.J., Higgins, S.T., Rizzuto, P. Behavioral economics of drug self-administration. IV. The effects of response requirement on consumption of and interaction between concurrently available coffee and cigarettes. <u>Psychopharm</u> 107:211-216, 1992. (RA)

DeGrandpre, R.J., Bickel, W.K., Higgins, S.T. Emergent equivalence relations between interoceptive (drug) and exteroceptive (visual) stimuli. <u>JEAB</u> 58:9-18, 1992. (RA)

DeGrandpre, R.J., Bickel, W.K., Hughes, J.R., Higgins, S.T. Behavioral economics of drug self-administration. III. A reanalysis of the nicotine regulation hypothesis. <u>Psychopharm</u> 108:1-8, 1992. (RA)

Oliveto, A.H., Bickel, W.K., Hughes, J.R., Higgins, S.T., Fenwick, J.W. Triazolam as a discriminative stimulus in humans. <u>Drug Alcohol Dep</u> 30:133-142, 1992. (RA)

Oliveto, A.H., Bickel, W.K., Hughes, J.R., Shea, P.J., Higgins, S.T., Fenwick, J.W. Caffeine drug discrimination in humans: Acquisition, specificity and correlation to self-reports. <u>JPET</u> 261:885-894, 1992. (RA)

Bickel, W.K., Oliveto, A.H., Kamien, J.B., Higgins, S.T., Hughes, J.R. A novel-response procedure enhances the selectivity and sensitivity of a triazolam discrimination in humans. <u>JPET</u> 264:360-367, 1993. (RA)

Bickel, W.K., Amass, L. The relationship of mean daily blood alcohol levels to admission, MAST, clinic absenteeism and depression in alcoholic methadone patients. <u>Drug Alcohol Dep.</u> (IP)

Bickel, W.K., DeGrandpre, R.J. A review of the effects of unit price on drug self-administration. In: Villarreal, J.E. (Ed.) <u>Drug Dependence: From Molecular to Societal Level</u>, Elsevier, Amsterdam. (IP)

Bickel, W.K., DeGrandpre, R.J. Modeling drug abuse policy in the behavioral economics laboratory. In: Green, L., Kagel, J. (Eds.) <u>Advances in Behavioral Economics</u>, Ablex, New York. (IP)

DeGrandpre, R.J., Bickel, W.K. Drug dependence as consumer demand. In: Green, L., Kagel, J. (Eds.) Advances in Behavioral Economics, Ablex, New York. (IP)

DeGrandpre, R.J., Bickel, W.K., Rizvi, S.A.T., Hughes, J.R. The behavioral economics of drug self-administration. VII. Effects of income on drug choice in humans. <u>JEAB</u>. (IP)

Kamien, J.B., Bickel, W.K., Hughes, J.R., Higgins, S.T., Smith, B. Drug discrimination by humans compared to nonhumans: Current status and future directions. <u>Psychopharm</u>. (IP)

Oliveto, A.H., Bickel, W.K., Hughes, J.R., Terry, S.Y., Higgins, S.T., Badger, G.J. Pharmacological specificity of the caffeine discriminative stimulus in humans: Effects of theophylline, methylphenidate and buspirone. <u>Behav Pharm</u>. (IP)

George E. Bigelow, Ph.D Behavioral Pharmacology Research Unit Behavioral Biology Research Center 5510 Nathan Shock Drive Johns Hopkins/Key Medical Center Baltimore, MD 21224

Preston, K.L., Sullivan, J.T., Strain, E.C. and Bigelow, G.E. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. <u>JPET</u> 262:271-291, 1992. (RA)

Strain, E.C., Preston, K.L., Liebson, I.A., Bigelow, G.E. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. <u>JPET</u> 261:985-993, 1992. (RA)

Weinhold, L.L., Preston, K.L., Farre, M., Liebson, I.A., Bigelow, G.E. Buprenorphine alone and in combination with naloxone in non-dependent humans. <u>Drug Alcohol Dep</u> 80:268-274, 1992. (RA)

Marilyn E. Carroll, Ph.D. Department of Psychiatry Box 392, UMHC University of Minnesota Minneapolis, MN 55455

Carroll, M.E., Carmona, G.N., May, S.A. Modifying drug-reinforced behavior by altering the economic conditions of the drug and a nondrug reinforcer. <u>JEAB</u>, 56:361-376, 1991. (RA)

Saddoff, D.A., Fischel, R.J., Carroll, M.E., Brockway, B. Chronic blood pressure radio telemetry in the rhesus macaque. <u>Laboratory Animal Sciences</u> 42:78-80, 1991. (RA)

Carroll, M.E., Carmona, G.G., May, S.A., Buzalski, S., Larson, C. Buprenorphine's effects on self-administration of smoked cocaine-base and orally-delivered phencyclidine, ethanol and saccharin in rhesus monkeys. <u>JPET</u> 261:26-37, 1992. (RA)

Carroll, M.E., Lac, S.T. The effects of buprenorphine on self-administration of cocaine and a nondrug reinforcer in rats. <u>Psychopharm</u> 106:439-446, 1992. (RA)

Carroll, M.E. Pharmacological and behavioral treatment of cocaine addiction: Animal models. NIDA Research Monograph on the proceedings of a neuroscience satellite symposium. (IP)

Carroll, M.E., Cormer, S.D. Phencyclidine (PCP) and hallucinogens. In: <u>The National Institute on Drug Abuse Fourth Triennial Report to Congress on Drug Abuse and Drug Abuse Research</u>. (IP)

Carroll, M.E., Comer, S.D. Inhalants. In: <u>The National Institute on Drug Abuse Fourth Triennial Report to Congress on Drug Abuse and Drug Abuse Research</u>. (IP)

Carroll, M.E., Comer, S.D. Phencyclidine. In: Jaffee, J.H. (Ed.), <u>The Encyclopedia of Drugs and Alcohol</u>, MacMillan:New York. (IP)

Carroll, M.E., Lac, S.T. Autoshaping IV cocaine self-administration in rats: Effects of a nondrug alternative reinforcer on acquisition. <u>Psychopharm</u>. (IP)

Carroll, M.E. The economic context of drug and nondrug reinforcers affects acquisition and maintenance of drug-reinforced behavior and withdrawal effects. Proceedings from the CPDD Symposium on Behavioral Economics. <u>Drug Alcohol Dep</u>. (SU)

Carroll, M.E., Carmona, G.N., Rodefer, J.S. A comparison of the effects of buprenorphine and dizocilpine on PCP self-administration and withdrawal in rhesus monkeys.(SU)

Carroll, M.E., Rodefer, J.S. The effects of income on choice between drug and an alternative nondrug reinforcer in monkeys. (SU)

Saltzman, D.A., Bonsack, M., Snyder, C., Carroll, M.E., Delaney, J.P., Leonard, A.S. Organ blood flow determinations under the influence of intravenous cocaine using radiolabeled microspheres. (SU)

Jonathan Kamien, Ph.D.
Department of Psychiatry
Human Behavioral Pharmacology Laboratory
University of Vermont
38 Fletcher Place
Burlington, VT 05401-1419

Kamien J.B., Spealman R.D. Modulation of the discriminative-stimulus effects of cocaine by buprenorphine. Beh Pharm 2:517-520, 1991. (RA)

Mello N.K., Lukas S.E., Kamien J.B., Mendelson J.H., Drieze, J., Cone, E.J. The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys. <u>JPET</u> 260:1185-1193, 1992. (RA)

Spealman, R.D., Bergman, J., Madras, B.K., Kamien, J.B., Melia, K.F. Role of D1 and D2 dopamine receptors in the behavioral effects of cocaine. <u>Neurochemistry International</u> 20(S):S147-S152, 1992. (RA)

- Bickel, W.K., Oliveto, A.H., Kamien, J.B., Higgins, S.T., Hughes, J.R. A novel-response procedure enhances the selectivity and sensitivity of a triazolam discrimination in humans. <u>JPET</u> 264:360-367, 1993. (RA)]
- Mello, N.K., Kamien, J.B., Lukas, S.E., Drieze, J., Mendelson, J. The effects of nalbuphine and butorphanol treatment on cocaine and food self-administration by rhesus monkeys. Neuropsychopharm 8:45-55, 1993. (RA)
- Kamien, J.B., Bickel, W.K., Hughes, J.R., Higgins, S.T., Smith, B. Drug discrimination by humans compared to nonhumans: Current status and future directions. <u>Psychopharm</u>. (IP)
- Mello N.K., Kamien J.B., Lukas S.E., Mendelson J.H., Drieze J.M., Sholar J.W. The effects of intermittent buprenorphine administration on cocaine self-administration by rhesus monkeys. <u>JPET</u>. (IP)
- Kamien, J.B., Bickel, W.K., Hughes, J.R., Higgins, S.T. The effects of $\Delta 9$ -tetrahydrocannabinol on repeated acquisition and performance of response sequences in humans. <u>Psychopharm.</u> (SU)
- Kamien, J.B., Bickel, W.K., Smith, B., Oliveto, A.H., Higgins, S.T., Hughes, J.R. Application of a novel-response procedure to human triazolam discrimination: Effects of lorazepam and buspirone. <u>JPET</u>. (SU)

Roland Griffiths, Ph.D.
Behavioral Pharmacology Research Unit
Behavioral Biology Research Center
Johns Hopkins Bayview Research Campus
5510 Nathan Shock Drive
Baltimore, MD 21224

- Ator, N.A., Griffiths, R.R. Oral self-administration of triazolam, diazepam and ethanol in the baboon: Drug reinforcement and benzodiazepine physical dependence. <u>Psychopharm</u> 108:301-312, 1992. (RA)
- Evans, S.M., Griffiths, R.R. Caffeine tolerance and choice in humans. <u>Psychopharm</u> 108:51-59, 1992. (RA)
- Griffiths, R.R., Sannerud, C.A., Ator, N.A., Brady, J.V. Zolpidem behavioral pharmacology in baboons: Self-injection, discrimination, tolerance and withdrawal. <u>JPET</u> 260:1199-1208, 1992. (RA)
- Preston, K.L., Wolf, B., Guarino, J.J., Griffiths, R.R. Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: Evaluation of abuse liability. <u>JPET</u> 262:707-720, 1992. (RA)
- Sannerud, C.A., Ator, N.A., Griffiths, R.R. Behavioral pharmacology of abecarnil in baboons: Self-injection, drug discrimination and physical dependence. <u>Behav Pharm</u> 3:507-516, 1992. (RA)
- Silverman, K., Evans, S.M., Strain, E.C., Griffiths, R.R. Withdrawal syndrome after the double-blind cessation of caffeine consumption. <u>NEJM</u> 327:1109-1114. (RA)
- Silverman, K., Griffiths, R.R. Low-dose caffeine discrimination and self-reported mood effects in normal volunteers. <u>JEAB</u> 57:91-107, 1992. (RA)

- Woodson, P.P., Griffiths, R.R. Control of cigarette smoking topography: Smoke filtration and draw resistance. Behav Pharm 3:99-111, 1992. (RA)
- Ator, N.A., Griffiths, R.R. Differential sensitivity to midazolam discriminative-stimulus effects following self-administered verses response-independent midazolam. <u>Psychopharm</u> 110:1-4, 1993. (RA)
- Griffiths, R.R., Evans, S.M., Guarino, J.J., Roache, J.D., Furman, W.R. Liebson, I., Schwam, E. Intravenous flumazenil following acute and repeated exposure to lorazepam in healthy volunteers: Antagonism and precipitated withdrawal. <u>JPET</u>. (IP)
- Griffiths, R.R., Troisi, J.R., Silverman, K., Mumford, G.K. Multiple-choice procedure: An efficient approach for investigating drug reinforcement in humans. <u>Behav Pharm</u>. (IP)
- Iguchi, M.Y., Handelman, L., Bickel, W.R., Griffiths, R.R. Benzodiazepine and sedative use/abuse by methadone maintenance clients. <u>Drug Alcoh Dep</u>. (IP)
- Lamb, R.J., Griffiths, R.R. Behavioral effects of pentobarbital, lorazepam, ethanol and chlorpromazine substitution in pentobarbital-dependent baboons. <u>JPET</u>. (IP)
- Sannerud, C.A., Ator, N.A., Griffiths, R.R. Behavioral pharmacology of tandospirone in baboons: Chronic administration and withdrawal, self-injection and drug discrimination. <u>Drug Alcoh Dep.</u> (IP)
- Troisi, J.R., Critchfield, T.S., Griffiths, R.R. Buspirone and lorazepam abuse liability in humans: Behavioral effects, subjective effects and choice. <u>Behav Pharm</u>. (IP)
- John R. Hughes, M.D.
 Department of Psychiatry
 Human Behavioral Pharmacology Laboratory
 University of Vermont
 38 Fletcher Place
 Burlington, VT 05401-1419
- Bickel, W.K., Hughes, J.R., DeGrandpre, R.J., Higgins, S.T., Rizzuto, P. Behavioral economics of drug self-administration. IV. The effects of response requirement on consumption of and interaction between concurrently available coffee and cigarettes. <u>Psychopharm</u> 107:211-216, 1992. (RA)
- Hughes, J.R. Tobacco withdrawal in self-quitters. JCCP 60:689-697, 1992. (RA)
- Hughes, J.R., Gulliver, S., Fenwick, J.W., Cruser, K., Valliere, W.A., Pepper, S.L., Shea, P.J., Solomon, L.J. Smoking cessation among self-quitters. <u>Hlth Psych</u> 11:331-334, 1992. (RA)
- Oliveto, A.H., Bickel, W.K., Hughes, J.R., Higgins, S.T., Fenwick, J.W. Triazolam as a discriminative stimulus in humans. <u>Drug Alcohol Dep</u> 30:133-142. (RA)
- Oliveto, A.H., Bickel, W.K., Hughes, J.R., Shea, P., Higgins, S.T., Fenwick, J.W. Caffeine drug discrimination in humans: Acquisition, specificity and correlation with self-reports. <u>JPET</u> 261:885-894. (RA)

Dr. Richard Meisch Department of Psychiatry The University of Texas Health Science Center at Houston 1300 Moursund Houston, Texas 77030-3497

Macenski, M.J., Meisch, R.A. Ethanol-reinforced responding of naive rhesus monkeys: Acquisition without induction procedures. <u>Alcohol</u> 9:547-554, 1992. (RA)

Macenski, M.J., Cutrell, E.B., Meisch, R.A. Concurrent pentobarbital- and saccharin-maintained responding: Effects of saccharin concentration and schedule conditions. <u>Psychopharm</u>. (IP)

Meisch, R.A., Bell, S.M., Lemaire, G.A. Orally self-administered cocaine in rhesus monkeys: Transition from negative or neutral behavioral effects to positive reinforcing effects. <u>Drug Alcohol Dep.</u> (IP)

Meisch, R.A., Lemaire, G.A. Drug self-administration. In: Van Haaren, F. (Ed.) <u>Methods in Behavioral Pharmacology</u>, Elsevier, Amsterdam. (IP)

Kenneth A. Perkins, Ph.D. Western Psychiatric Institute and Clinic University of Pittsburgh 3811 O'Hara Street Pittsburgh, PA 15213

Caggiula, A.R., Epstein, L.H., Antelman, S.M., Saylor, S., Perkins, K.A., Knopf, S., Stiller, R.L. Conditioned tolerance to the anorectic and corticosterone-elevating effects of nicotine. <u>Pharm Biochem Behav</u> 40:53-59, 1991. (RA)

Perkins, K.A., Epstein, L.H., Sexton, J.E., Stiller, R.L., Jacob, R.G. Effects of dose, gender and level of physical activity on acute metabolic response to nicotine. <u>Pharm Biochem Behav</u> 40:203-208, 1991. (RA)

Perkins, K.A., Stiller, R.L., Jennings, J.R. Acute tolerance to the cardiovascular effects of nicotine. <u>Drug Alcohol Depen</u> 29:77-85, 1991. (RA)

Perkins, K.A. Metabolic effects of cigarette smoking. J App Physiol 72:401-409, 1992. (RA)

Perkins, K.A. Effects of tobacco smoking on caloric intake. Br J Addict 87:193-206, 1992. (RA)

Perkins, K.A., Epstein, L.H., Sexton, J.E., Solberg-Kassel, R.D., Stiller, R.L., Jacob, R.G. Effects of nicotine on hunger and eating in male and female smokers. <u>Psychopharm</u> 106:53-59, 1992. (RA)

Perkins, K.A., Grobe, J.E. Increased desire to smoke during acute stress. <u>Br J Addict</u> 87:1037-1040, 1992. (RA)

Perkins, K.A., Grobe, J.E., Epstein, L.H., Caggiula, A.R., Stiller, R.L. Effects of nicotine on subjective arousal may be dependent on baseline subjective state. <u>J Substance Abuse</u> 4:131-141, 1992. (RA)

Perkins, K.A., Grobe, J.E., Fonte, C., Breus, M. 'Paradoxical' effects of smoking on subjective stress versus cardiovascular arousal in males and females. <u>Pharm Biochem Behav</u> 42:301-311, 1992. (RA)

Perkins, K.A., Grobe, J.E., Stiller, R.L., Fonte, C., Goettler, J.E. Nasal spray nicotine replacement suppresses cigarette smoking desire and behavior. <u>Clin Pharm Ther</u>. (IP)

Ovide F. Pomerleau, Ph.D. The University of Michigan Department of Psychiatry Behavioral Medicine Program 475 Market Place, Suite L Ann Arbor, MI 48108

Pomerleau, C.S., Pomerleau, O.F. Euphoriant effects of nicotine in smokers. <u>Psychopharm</u> 108:460-465, 1992. (RA)

Pomerleau, O.F., Flessland, K.A., Pomerleau, C.S., Hariharan, M. Controlled dosing of nicotine via an Intranasal Nicotine Aerosol Delivery Device (INADD). <u>Psychopharm</u> 15:519-526, 1992. (RA)

Pomerleau, C.S., Pomerleau, O.F., Flessland, K.A., Basson, S.M. Relationship of Tridimensional Personality Questionnaire scores and smoking variables in female and male smokers. J Sub Abuse 4:143-154, 1992. (RA)

Pomerleau, O.F., Spring, B., Pomerleau, C.S. Serotonergic agents modulate weight gain following smoking cessation. <u>NIDA Research Monograph 119, Problems of Drug Dependence:</u> <u>Proceedings of the 53rd Annual Scientific Meeting</u>, USDHHS, pp 469, 1992. (RA)

Pomerleau, O.F. Nicotine and the central nervous system: Biobehavioral effects of cigarette smoking. <u>Am J Med</u>. (IP)

Pomerleau, O.F., Collins, A.C., Shiffman, S., Pomerleau, C.S. Why some people smoke and others do not: New perspectives. <u>J Consult Clin Psychol</u>. (IP)

Pomerleau, O.F., Hariharan, M., Pomerleau, C.S., Cameron, O.G., Guthrie, S.K. Differences between smokers and never-smokers in sensitivity to nicotine: A preliminary report. <u>Br J Addict</u> (IP)

Pomerleau, O.F., Pomerleau, C.S., Cameron, O.G., Hariharan, M. Sensitivity to nicotine in smokers and never-smokers. <u>NIDA Research Monograph 119, Proceedings of the 54th Annual Scientific Meeting</u>. (IP)

Dr. William Woolverton Department of Psychiatry The University of Chicago 5841 S. Maryland Avenue Chicago, IL 60637

Nader, M.A., Woolverton, W.L. Effects of increasing response requirement on choice between cocaine and food in rhesus monkeys. <u>Psychopharm</u> 108:295-300, 1992. (RA)

Weed, M.R., Vanover, K.E., Woolverton, W.L. Reinforcing effect of the D1 dopamine agonist SKF 81297 in rhesus monkeys. <u>Eur J Pharmacol</u>. (IP)

TC	cm	A D	RIRI	JOGRA	DHV	FODM
72	GID.	AK	DIDL	JUGKA	PHI	rurw

(RA) Published, reprints available (IP) In Press, reprints will be mailed after publication (NA) Reprints unavailable (SU) Submitted
In submitting your entries, use any useful format. Mail this form to:
Dr. John R. Hughes Department of Psychiatry University of Vermont 38 Fletcher Place Burlington, Vermont 05401
Note: If the response cost is less to just mail a copy of the preprint or reprint, please feel free to do so with ISGIDAR written on the envelope or the paper itself.
Address for reprints:
·
Citations (in alphabetical order)